Johnson & Johnson raises dividend for 64th consecutive year; maintains AAA rating
What happened
Johnson & Johnson raised its dividend for the 64th consecutive year. The company holds one of only two AAA credit ratings among U.S. companies, a rating higher than the U.S. government's own rating. The company operates two businesses: prescription drugs through its Innovative Medicine unit and surgical and orthopedic equipment.
From aol.com
Why it matters
The sustained dividend increases and the AAA credit rating signal strong financial stability. Healthcare spending, including prescriptions and procedures, is noted as remaining stable during both recessions and booms.
From aol.com
Who's involved
- Johnson & JohnsonU.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Johnson & JohnsonSpeculative
The AAA credit rating and consistent dividend increases could affect the company's market price and regulatory standing.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Medtech
medical education facility founded in 2004 in Indianapolis, U.S
Related events
- Johnson & Johnson was referenced in a recent news report concerning New York City.
- Johnson & Johnson joins the USMN initiative.
- Johnson & Johnson's MedTech segment reported sales below expectations and is facing an investigation into federal securities law violations.
- Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.